## RGNX: REGENXBIO Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity**
- Source: Investing.com Nigeria | 20251215T190912 | Bullish | Relevance: 100%
- Leerink Partners has increased its price target for Regenxbio Inc. (NASDAQ:RGNX) to $20 from $16, maintaining an Outperform rating, due to an expanded Duchenne muscular dystrophy (DMD) opportunity. The firm highlighted Regenxbio's potential to differentiate on safety for its RGX-202 DMD treatment and cited upcoming catalysts including expected topline data, regulatory submissions, and potential approvals for other treatments. The company's financial data indicates strong liquid assets but a high cash burn rate.

**2. Leerink Partners Maintains REGENXBIO (RGNX) Outperform Recommendation**
- Source: Nasdaq | 20251216T070300 | Bullish | Relevance: 100%
- Leerink Partners has reiterated an Outperform recommendation for REGENXBIO (RGNX). Analyst forecasts suggest a 132.04% upside with an average one-year price target of $32.09/share. Institutional ownership data shows 329 funds holding positions in RGNX, with key holders including Redmile Group and Jpmorgan Chase.

**3. Regenxbio (RGNX): Leerink Partners Raises Price Target to USD 20**
- Source: GuruFocus | 20251215T190912 | Bullish | Relevance: 100%
- Leerink Partners has maintained its 'Outperform' rating on Regenxbio (RGNX) and increased the price target from USD 16.00 to USD 20.00, reflecting a continued positive outlook on the biotech company. This update, along with others from various analysts, suggests an average target price of $31.77 for RGNX, implying a significant upside from its current price. Regenxbio, a biotechnology company, focuses on developing gene therapies for metabolic, neurodegenerative, and retinal diseases, with most of its revenue derived from the United States.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $20 | $16 | +25% |
| 2025-11-20 | Chardan Capital | $52 | $52 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Outperform |
| 2025-11-20 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.0% (+109.6%)
- Blackrock Inc.: 12.6% (-5.7%)
- Redmile Group, LLC: 9.3% (-1.7%)
- Vanguard Group Inc: 6.6% (-2.4%)
- State Street Corpora: 3.9% (+7.7%)

### Key Risks

1. Elevated short interest (13.0%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.26 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.7x). Revenue growth strong at 39% YoY. Analyst sentiment positive (1 raises, avg +25%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.7B |
| Beta | 1.14 |
| 52W Range | $5.04 - $14.93 |
| Short Interest | 13.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.26 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -0.9% to 1.9% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.1pp (needs >3.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.86% (CS: 42) | Neutral |
| RSI_14 | 54.1 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.392x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $13.17
- **Stop Loss:** $11.39 (13.5% risk)
- **Target:** $14.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 606
- **Position Value:** $7,981.02
- **Portfolio %:** 7.98%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-03-12 (Est: $-0.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.30 | $-1.20 | +7.6% |
| 2025Q2 | $-1.05 | $-1.38 | -30.8% |
| 2025Q1 | $0.49 | $0.12 | -75.3% |
| 2024Q4 | $-1.08 | $-1.01 | +6.9% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*